Chemed Corp. (NYSE:CHE) – KeyCorp raised their FY2017 earnings estimates for Chemed Corp. in a report released on Monday. KeyCorp analyst J. Gurda now expects that the company will earn $4.73 per share for the year, up from their previous estimate of $4.43. KeyCorp currently has a “Hold” rating on the stock. KeyCorp also issued estimates for Chemed Corp.’s FY2018 earnings at $8.91 EPS.
Chemed Corp. (NYSE:CHE) last posted its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million for the quarter, compared to analyst estimates of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The business’s revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.73 EPS.
Other analysts have also issued research reports about the company. Zacks Investment Research raised Chemed Corp. from a “hold” rating to a “buy” rating and set a $216.00 price objective on the stock in a report on Monday, September 18th. Oppenheimer Holdings, Inc. lifted their price objective on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. TheStreet lowered Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $209.00 price objective on shares of Chemed Corp. in a report on Monday, July 31st. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $224.33.
In related news, CEO Kevin J. Mcnamara sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total transaction of $2,234,200.00. Following the completion of the transaction, the chief executive officer now owns 170,016 shares in the company, valued at approximately $37,984,974.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total value of $197,460.00. Following the transaction, the insider now owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The disclosure for this sale can be found here. Insiders have sold a total of 12,250 shares of company stock valued at $2,698,968 in the last 90 days. 4.90% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC bought a new position in shares of Chemed Corp. during the 2nd quarter worth approximately $120,000. Pacad Investment Ltd. lifted its position in shares of Chemed Corp. by 250.0% during the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after buying an additional 500 shares during the period. IFP Advisors Inc lifted its position in shares of Chemed Corp. by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after buying an additional 662 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Chemed Corp. by 12.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after buying an additional 83 shares during the period. Finally, MCF Advisors LLC bought a new position in shares of Chemed Corp. during the 3rd quarter worth approximately $152,000. Institutional investors and hedge funds own 97.24% of the company’s stock.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
What are top analysts saying about Chemed Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemed Corp. and related companies.